Persistent Fibroblast Activation Predicts Heart Failure Progression: [68Ga]FAPI-46 PET/MRI Reveals Distinct Patterns in Ischemic and Nonischemic Cardiomyopathy
Posted inCardiology news

Persistent Fibroblast Activation Predicts Heart Failure Progression: [68Ga]FAPI-46 PET/MRI Reveals Distinct Patterns in Ischemic and Nonischemic Cardiomyopathy

A prospective case-control study demonstrates that myocardial fibroblast activation persists in heart failure patients and follows distinct spatial patterns depending on etiology. Using [68Ga]FAPI-46 PET/MRI, researchers found that higher baseline uptake predicts worse outcomes, suggesting potential for risk stratification and targeted antifibrotic therapy development.
Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities
Posted inCardiology news

Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities

A landmark study reveals that exercise-induced multi-organ physiologic deficits strongly predict incident heart failure with preserved ejection fraction (HFpEF). Using invasive cardiopulmonary testing, metabolomics, and genomics across over 6,000 individuals, researchers identified seven distinct exercise deficits that, when combined, confer nearly 4-fold higher cardiovascular risk and implicate shared metabolic pathways with obesity, diabetes, and renal disease.
Decoding the Heart Failure Peptidome: A Cross-Sectional Study Uncovers Novel Biomarkers and Patient Clusters
Posted inCardiology news

Decoding the Heart Failure Peptidome: A Cross-Sectional Study Uncovers Novel Biomarkers and Patient Clusters

A groundbreaking mass spectrometry study analyzing 486 heart failure patients and 98 controls identified over 21,000 unique peptides, revealing 1,924 differentially expressed peptides. The research highlights angiotensin-related peptides, natriuretic peptide pathways, and cardiometabolic regulators as key outcome predictors, while identifying three distinct patient clusters with varying survival probabilities.
Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes
Posted inCardiology Diabetes & Endocrinology news

Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes

Researchers from the ARIC study have identified five specific proteomic markers that uniquely predict heart failure risk in individuals with diabetes. These findings, including four novel proteins, suggest distinct pathophysiological pathways for diabetic cardiomyopathy and offer new targets for precision screening and therapeutic intervention.
Ethnic Minority Patients with Heart Failure in England Achieve Superior Survival: The Crucial Role of Specialist Care and Medication Adherence
Posted inCardiology news Public Health

Ethnic Minority Patients with Heart Failure in England Achieve Superior Survival: The Crucial Role of Specialist Care and Medication Adherence

A large-scale analysis of 239,890 patients in England reveals that Black, Asian, and mixed-ethnicity patients hospitalized for heart failure have significantly lower mortality rates than White patients, largely due to better pharmacological management and specialist care within a universal healthcare system.
Transcatheter Edge-to-Edge Repair Superior to Medical Therapy in Atrial Functional Mitral Regurgitation: Evidence from Real-World Registries
Posted inCardiology news

Transcatheter Edge-to-Edge Repair Superior to Medical Therapy in Atrial Functional Mitral Regurgitation: Evidence from Real-World Registries

A propensity score-based study demonstrates that transcatheter edge-to-edge repair (TEER) significantly reduces mortality and heart failure hospitalizations in patients with atrial functional mitral regurgitation compared to medical therapy, especially when achieving low residual regurgitation.
CRLF1 Secreted by Cardiac Fibroblasts: A New Driver and Potential Therapeutic Target for Hypertrophic Cardiomyopathy
Posted inCardiology Internal Medicine news

CRLF1 Secreted by Cardiac Fibroblasts: A New Driver and Potential Therapeutic Target for Hypertrophic Cardiomyopathy

This article explores a groundbreaking study identifying CRLF1, a protein secreted by cardiac fibroblasts, as a key driver of Hypertrophic Cardiomyopathy (HCM). This paracrine signaling mechanism offers a potential universal therapeutic target for patients regardless of their specific genetic mutations.